IL17A and bronchiectasis: Elevated IL-17A and IL-23 in bronchiectasis compared to healthy and COPD controls; reduced Th17 inflammation with long-term macrolide therapy. Evidence from blood, BALF, and tissue samples (in vivo), cytokine analysis (in vitro) (59–65)